Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 104Thoracic 9Gastrointestinal 8CNS 4Other solid neoplasm 2Head & Neck 1Genitourinary 1

Conditions

Solid Tumor 1HER2-expressing Advanced Solid Tumors 1

Interventions

Cisplatin 145pembrolizumab 129Carboplatin 125Injections 108Pemetrexed 97Paclitaxel 97Gemcitabine 85Irinotecan 75Nivolumab 71Cyclophosphamide 71Docetaxel 68Bevacizumab 57Oxaliplatin 49Fluorouracil 48atezolizumab 46Capecitabine 46Etoposide 42Leucovorin 41tislelizumab 40toripalimab 36fludarabine 32Ipilimumab 30Drug Therapy 30Topotecan 29durvalumab 28Vincristine 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 26Specimen Handling 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × pyrotinib × Other solid neoplasm × Clear all
NCT06015048 2024-08-05

A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Recruiting
364 enrolled
Other solid neoplasm

HER2-expressing Advanced Solid Tumors

NCT04179656 2019-11-27

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Tianjin Medical University Second Hospital

Phase 2 Unknown
100 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡